What Мелатонин Treats: Main Uses and Benefits

Melatonin is used across domains where additional symptomatic support is needed to help address the appropriate sleep-wake timing. It provides symptomatic relief by managing the cluster of issues resulting from circadian misalignment. Melatonin may assist with certain conditions like jet lag and delayed sleep-wake phase disorder.

The medication is commonly used to help with sleep onset difficulties and delayed sleep periods. Specific conditions where its use is relevant include Delayed Sleep-Wake Phase Sleep Disorder (DSWPD), Jet Lag Syndrome, and the management of delayed and irregular sleep patterns frequently seen in children and adolescents with certain neurodevelopmental disabilities.

“The symptomatic support provided assists patients by helping to maintain a sense of stability when symptoms are more noticeable, and supports general well-being during symptomatic periods.”

In these contexts, Melatonin may assist with adjusting the timing of the sleep period to help manage sleep initiation. This supportive benefit helps patients cope more steadily with symptom fluctuations, particularly older adults (age 55 and over) and shift workers experiencing acute distress from schedule changes.

---

Quick Fact: Relief for Irregular Sleep Timing Melatonin is applied in addressing conditions presenting with systemic or localized discomfort due to an internal clock mismatch, offering symptomatic support when sleep-wake timing interferes with daily functioning.

Regulatory References

1. NIH NCCIH Melatonin Overview

Official Eligibility Profile: Who Can and Cannot Use Melatonin

Regulatory documentation strictly defines the populations for whom melatonin use is either permitted, restricted, or prohibited.

Classification	Status (Regulatory Stated)
Contraindicated Populations	Hypersensitivity to the active substance or any excipients.
Not Recommended	Patients with autoimmune diseases (due to lack of clinical data).
Not Recommended	Patients with moderate or severe hepatic impairment (due to significantly reduced clearance).
Age-Related Eligibility	Use is limited to specific age ranges for approved indications (e.g., adults 55 years, or specific pediatric populations with neurodevelopmental disorders). General use in children and adolescents is often not established or not recommended.
Pregnancy and Lactation	Not recommended during pregnancy or breastfeeding, as clinical data are insufficient and risk to the fetus/infant cannot be excluded.
Conditional Use/Caution	Caution is advised for patients with renal impairment or epilepsy. Patients with rare hereditary problems of galactose intolerance, LAPP lactase deficiency, or glucose-galactose malabsorption should not take certain formulations containing lactose.

This profile represents formal regulatory statements on eligibility and non-eligibility and does not include therapeutic advice.

Pharmacokinetic Interactions (Exposure Modification)

The metabolism of Melatonin is primarily regulated by the CYP1A2 enzyme. Certain co-administered medicines that inhibit this enzyme can increase the body's exposure to Melatonin. The combination with Fluvoxamine is officially documented to be avoided as it is a potent inhibitor of CYP1A2 and CYP2C19, resulting in a documented 17-fold increase in Melatonin concentration (AUC). Other medicines that may increase Melatonin levels include oestrogens (in contraceptives or HRT), quinolones, Cimetidine, and 5- or 8-methoxypsoralen. Conversely, CYP1A2 inducers such as Carbamazepine, Rifampicin, and Cigarette Smoking are documented to reduce Melatonin's plasma concentration.

Pharmacodynamic and Co-administration Restrictions

Melatonin may enhance the sedative properties of other agents, leading to additive CNS effects. This includes Benzodiazepines and non-benzodiazepine hypnotics like Zolpidem, with co-administration resulting in officially reported increased impairment of attention and coordination. The use of Alcohol is explicitly prohibited before, during, or after administration, as it reduces the product’s effectiveness on sleep. The prolonged-release formulation is subject to a timing rule and must be taken after eating. Furthermore, use is not recommended in patients with hepatic impairment due to decreased clearance, or in those with autoimmune diseases due to insufficient clinical data in these populations.

Central Clock Regulation through MT1 and MT2 Agonism

This mechanism focuses on Melatonin receptor type 1 ( MT1) and type 2 ( MT2) agonism within the brain's Suprachiasmatic Nucleus (SCN). MT1 activation inhibits the SCN's primary neuronal firing, which transmits the 'wake signal.' MT2 activation adjusts the timing of the internal body clock (phase shifting), leading directly to the initiation of the physiological signal for sleep.

---

Core Body Temperature Modulation

The compound's action on hypothalamic receptors initiates peripheral vasodilation, which increases heat loss and causes a key, transient lowering of core body temperature. This controlled hypothermia is an intrinsic biological signal that reinforces the central drive to sleep and initiates the physiological transition from an alert to a resting state.

---

Receptor-Independent Antioxidant Modulation

Beyond receptor activity, Мелатонин and its metabolites act as direct free radical scavengers that neutralize destructive Reactive Oxygen Species (ROS) throughout the body and brain. This receptor-independent action contributes to cellular stability and modulates cellular redox balance, shaping the compound's activity in processes beyond circadian function.

How Melatonin is Used in Clinical Practice

Melatonin is administered exclusively through the oral route, typically formulated as prolonged-release tablets, immediate-release tablets, or capsules. The use is structured around specific timing and duration to help regulate the sleep-wake cycle, as outlined by regulatory guidelines.

---

Official Dosing and Administration Patterns

The most common dose for specific prolonged-release products used in primary insomnia in older adults (age 55 and over) is 2 mg once daily. For the short-term treatment of jet lag, the dose generally ranges from 1 mg to 5 mg daily, with official labeling restricting use to a maximum of 5 consecutive days per course. For specific, chronic circadian disorders, a prescription analogue is officially dosed at 20 mg once daily.

---

Administration Requirements

The effectiveness of Melatonin is highly dependent on the precise timing of administration. The dose must be taken once daily at a specific time, generally 1 to 2 hours before the intended bedtime. This must be done consistently, taking the dose at the same time every night for chronic conditions.

Food Relationship and Tablet Handling: Prolonged-release forms must be taken after food to ensure the intended release profile and must be swallowed whole. These tablets must not be cut, crushed, or chewed, as this compromises the formulation. If a daily dose is forgotten, it must be skipped, and a double dose must never be taken. Use in individuals with hepatic impairment is generally not recommended due to reduced clearance.

Research Evidence / Overview of Studies for Melatonin

The body of research on Melatonin consists mainly of Randomized Controlled Trials (RCTs) and Systematic Reviews that combine results from many individual studies. The purpose of this research is to examine the patterns observed in studies related to sleep timing. Findings describe group patterns observed in the studies and help contextualize how patients reported their experiences.

---

Evidence for Use in Circadian Rhythm Sleep Disorders

Melatonin was studied for conditions like Delayed Sleep-Wake Phase Sleep Disorder (DSWPD). Studies relevant in trials assessing this short-term symptom pattern included children, adolescents, and adults. Researchers examined Sleep Onset Latency (the time it takes to fall asleep) and Total Sleep Time. Studies report measurements taken of the time patients took to fall asleep, with data showing patterns related to measurements of the body's internal timing. Research highlights that the patterns observed may be influenced by the precision of administration timing.

---

Evidence for Use in Managing Acute Circadian Adjustment

Research into Jet Lag Syndrome has explored Melatonin's evaluation in studies following travel across multiple time zones. Studies were typically short-term RCTs that explored healthy adult air travelers. Research examined outcomes related to systemic or functional imbalance by monitoring subjective ratings of global jet lag symptoms (such as fatigue and impaired mental efficiency).

Evidence is limited in several areas. Much of the evidence is derived from studies that had modest sample sizes, and comparative evidence is lacking against other methods for adjusting the internal clock.

---

Evidence in Special Populations: Children and Neurodevelopmental Conditions

Melatonin was evaluated in studies involving children and adolescents who had delayed or irregular sleep patterns associated with neurodevelopmental disabilities, such as Autism Spectrum Disorder (ASD). These studies explored short-term symptom changes, monitoring outcomes reflecting daily functioning, alongside measurements of sleep.

Long-term effects are not fully established, particularly regarding potential changes during pubertal development, and data for these specific neurodevelopmental groups remain insufficient.

Key Studies & References Melatonin: What You Need To Know - National Center for Complementary and Integrative Health (NCCIH)

Common questions about Мелатонин (FAQ)

Q: How should I store this medication?

Official regulatory documents indicate that this medicinal product does not require any special storage conditions. Referencing the official product information will provide the most specific details.

Q: What happens if I drink alcohol while taking this medicine?

Official product information advises against consuming alcohol while taking this medication. The combination of this medicine and alcohol may lead to an increase in side effects, such as sleepiness (somnolence) and dizziness. The combination of these substances is advised against in the official product labeling.

Q: Should I take this medicine with food or on an empty stomach?

According to the Dosage and Administration section of the official label, the capsule formulation of this medication may be given orally with or without food. Specific formulations, such as extended-release tablets, might have different instructions. Referencing the directions provided for your specific product is key.

Q: Does this medication cause weight gain?

Regulatory documents list weight gain as one of the most commonly reported side effects observed in adult clinical trials. This reaction was reported at a rate of 5% or greater and was at least twice the rate observed in patients taking a placebo.

Q: Does it make you sleepy?

Official product information notes that sleepiness (somnolence) and dizziness are among the most frequent adverse reactions reported. Because of these effects, the regulatory text includes a warning that this medication may impair a person's ability to drive or operate heavy machinery.

Q: Is it safe to use this long-term?

For certain uses, such as Generalized Anxiety Disorder (GAD), regulatory agencies advise that the need for continued treatment should be regularly reassessed. Official post-marketing reports have indicated that this drug can cause dependence, and patients with a history of substance abuse may face a higher risk. The length of treatment should align with recommendations from healthcare professionals.

Q: Can children 2 years old use it?

According to the official product label, for the treatment of partial-onset seizures, this medication is approved for use in pediatric patients starting at 1 month of age and older, which includes children 2 years old. Its approval for other conditions, such as nerve pain (diabetic neuropathy) or fibromyalgia, is typically limited to adult patients.

How to Store and Dispose of Melatonin

Official regulations require melatonin to be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container, which should remain tightly closed, and be protected from light, moisture, and excessive heat. Storage must ensure the product is out of the sight and reach of children.

---

For disposal, the preferred method for unused or expired melatonin is through an official drug take-back program. If a take-back site is unavailable, the medication should be mixed with an undesirable substance (e.g., dirt, used coffee grounds) and sealed in a container for disposal in the household trash. Melatonin must not be flushed down the toilet or discarded into the wastewater system.